CN-121978152-A - Biomarker combination for liver cancer prognosis evaluation and application thereof

Abstract

The invention discloses a biomarker combination for liver cancer prognosis evaluation and application thereof, wherein the biomarker combination consists of H4A2, H4CH, H4A1, V1TG, H4PL, H4FC, tyrosine, 2-ketoglutarate, lysine, L2TG and glycine. The biomarker combination provided by the invention can be applied to preparation of products for prognosis evaluation of liver cancer, and the liver cancer recurrence prediction model for evaluating prognosis of liver cancer, which is constructed based on the biomarker combination provided by the invention, has high prediction efficiency and can rapidly and accurately evaluate the recurrence risk of liver cancer.

Inventors

• PAN MINGXIN
• GUO HONGBO
• TAN HONGKUN
• XU YUYAN
• FU SHUNJUN
• YUE QU
• LAN YUFEI

Assignees

• 南方医科大学珠江医院

Dates

Publication Date

20260505

Application Date

20260401

Claims (6)

1. 1. Biomarker combination for prognosis evaluation of liver cancer, characterized in that the biomarker combination consists of high density lipoprotein-apolipoprotein A2-4 th fraction, high density lipoprotein-cholesterol-4 th fraction, high density lipoprotein-apolipoprotein A1-4 th fraction, very low density lipoprotein-triglyceride-1 st fraction, high density lipoprotein-phospholipid-4 th fraction, high density lipoprotein-free cholesterol-4 th fraction, tyrosine, 2-ketoglutarate, lysine, low density lipoprotein-triglyceride-2 nd fraction and glycine.
2. 2. Use of the biomarker combination according to claim 1 in the manufacture of a product for prognosis evaluation of liver cancer.
3. 3. Use of a product for detecting the metabolic level of each biomarker in a biomarker combination according to claim 1 in a sample in the manufacture of a product for prognosis evaluation of liver cancer.
4. 4. The use according to claim 3, wherein the sample is plasma.
5. 5. The use according to claim 3 or 4, wherein the liver cancer is hepatocellular carcinoma.
6. 6. The use according to claim 5, wherein the product for detecting the metabolic level of each biomarker in the biomarker combination according to claim 1 in a sample is a reagent, kit, chip and/or instrument suitable for detecting the metabolic level of each biomarker in the biomarker combination according to claim 1 in a sample by nuclear magnetic resonance spectroscopy.

Description

Biomarker combination for liver cancer prognosis evaluation and application thereof Technical Field The invention belongs to the technical field of biological medicines, and relates to a biomarker combination for liver cancer prognosis evaluation and application thereof. Background Primary liver cancer (abbreviated as liver cancer) is a malignant tumor with high morbidity and mortality in the global scope. Whereas hepatocellular carcinoma (Hepatocellular carcinoma, HCC) is the major pathological type of liver cancer. Although surgical resection, liver transplantation and local ablation are recommended for early HCC treatment (barcelona clinical liver cancer stage, BCLC 0-a stage), the postoperative recurrence rate remains high, severely affecting patient prognosis. The accurate grasp of prognosis prediction for liver cancer can help clinicians to more scientifically, accurately and individually formulate treatment schemes, reasonably allocate medical resources and improve life quality of patients, and the development of accurate prognosis prediction tools is important for identifying high-risk patients and guiding personalized treatment. Disclosure of Invention The invention mainly aims to provide a biomarker combination for liver cancer prognosis evaluation and application thereof, so as to solve at least one of the technical problems. According to a first aspect of the present invention, there is provided a biomarker combination for prognosis evaluation of liver cancer, which consists of high density lipoprotein-apolipoprotein A2-4 th fraction (HDL-4 Apo-A2, H4 A2), high density lipoprotein-cholesterol-4 th fraction (HDL-4 Cholesterol,H4CH), high density lipoprotein-apolipoprotein A1-4 th fraction (HDL-4 Apo-A1, H4 A1), very low density lipoprotein-triglyceride-1 st fraction (VLDL-1 Triglycerides,V1TG), high density lipoprotein-phospholipid-4 th fraction (HDL-4 Phospholipids,H4PL), high density lipoprotein-free cholesterol-4 th fraction (HDL-4 Free Cholesterol,H4FC), tyrosine (Tyrosine), 2-ketoglutaric acid (2-Oxoglutaric acid), lysine (Lysine), low density lipoprotein-triglyceride-2 nd fraction (LDL-2 Triglycerides,L2TG) and Glycine (Glycine). The biomarker combination consisting of 11 metabolites or blood lipid indexes provided by the invention can be applied to rapidly and accurately evaluating the prognosis situation of liver cancer, and is particularly suitable for effectively predicting the recurrence risk of HCC. According to a second aspect of the present invention there is provided the use of a biomarker combination according to the present invention in the manufacture of a product for prognosis evaluation of liver cancer. Based on the biomarker combination provided by the invention, a liver cancer recurrence prediction model with high prediction efficiency and capable of being used for assessing liver cancer prognosis can be constructed through various algorithms. The model for predicting the recurrence of the HCC is constructed based on stepwise Cox regression screening variables, forward stepwise regression (StepCox [ Forward ]), and Random Survival Forest (RSF), can reach a C index of 0.76 in a verification set, and in a complete queue containing 88 HCC patients, the AUC for predicting 2-year recurrence of the hepatocellular carcinoma is 0.811, which is superior to the AUC for predicting 2-year recurrence of the hepatocellular carcinoma of traditional stage systems such as a Chinese liver cancer stage (CNLC) system, a Barcelona clinical liver cancer stage (BCLC) system and the like. In some embodiments, the liver cancer recurrence prediction model can be deployed as an application program, a small program, APP and the like, and the recurrence risk of a liver cancer patient can be known only by inputting the metabolic levels of 11 biomarkers in the biomarker combination provided by the invention in plasma. According to a third aspect of the present invention there is provided the use of a product for detecting the metabolic levels of H4A2, H4CH, H4A1, V1TG, H4PL, H4FC, tyrosine, 2-ketoglutarate, lysine, L2TG and glycine in a sample for the preparation of a product for prognosis evaluation of liver cancer. In some embodiments, the product of detecting the metabolic levels of H4A2, H4CH, H4A1, V1TG, H4PL, H4FC, tyrosine, 2-ketoglutarate, lysine, L2TG, and glycine in the sample can be a reagent, kit, chip, and/or instrument that can quantitatively detect the metabolic levels of H4A2, H4CH, H4A1, V1TG, H4PL, H4FC, tyrosine, 2-ketoglutarate, lysine, L2TG, and glycine in the sample using any known in the art. In some embodiments, the product for detecting the metabolic levels of H4A2, H4CH, H4A1, V1TG, H4PL, H4FC, tyrosine, 2-ketoglutarate, lysine, L2TG, and glycine in the sample may be a reagent, kit, chip, and/or instrument suitable for detecting the metabolic levels of H4A2, H4CH, H4A1, V1TG, H4PL, H4FC, tyrosine, 2-ketoglutarate, lysine, L2TG, and glycine in the sample by nuclear magnetic resona